Navigation Links
Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962)
Date:11/6/2009

WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- America's Specialty Medicines Companies (ASMC), an informal working group of mid-market and smaller innovator pharmaceutical companies, today expressed concerns about H.R. 3962, the "Affordable Health Care for America Act," introduced by House Democrats last Thursday. These smaller companies fear that the cumulative effect of a host of provisions in H.R. 3962 will hinder their efforts to bring new medicines to market.

From required rebates to mandated discounts to new regulations, H.R. 3962 repeatedly raises new barriers for small companies seeking to fund life-saving research. Unlike larger companies, smaller companies typically must use cash generated from the sale of their own products for research. Unfortunately, the bill starves them of those necessary revenues. Its new burdens will damage the viability of small companies, and ultimately, put at risk the health of future patients who need medicines that smaller companies are more likely to develop.

Smaller companies generate much of the innovation in the pharmaceutical industry. Their work ranges over the entire spectrum from drugs for some of the most common diseases like cancer and diabetes to those for smaller, underserved populations with rare diseases. Without smaller companies' investment in the research and development of breakthrough products, many patients would go without any effective treatment. In many cases, these very treatments contain costs by eliminating the need for more expensive care.

"Small pharmaceutical companies often bring needed specialty medications to market when no one else will. Unfortunately, H.R. 3962 would stifle that innovation and prevent those efforts. Ultimately, the patients who need these medicines will suffer most," said Steve Cannon, an attorney representing ASMC.

But the damage runs deeper. H.R. 3962 will cut off small drug companies' ability to bring drugs developed overseas to the U.S. market as well. Small companies frequently license U.S. rights to those drugs, conduct U.S. clinical trials on them, and seek U.S. approval of them. Much of that economic activity would stop under H.R. 3962 - hurting the U.S. economy, killing U.S. jobs, and depriving U.S. patients of needed drugs.

Despite our concerns, ASMC looks forward to continuing to work with Congress to produce health care legislation that will produce better care and better drugs for all Americans.

SOURCE America's Specialty Medicines Companies


'/>"/>
SOURCE America's Specialty Medicines Companies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
3. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
6. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
7. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
8. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
9. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
10. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
11. VA Statement on Smoking Cessation Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):